The estrogen receptor plays a critical role in the pathogenesis and clinical behavior of breast cancer. To better understand the molecular basis of estrogen-dependent forms of this disease we studied gene expression profiles from 53 primary breast cancer biopsies. Gene expression data for more than 7000 genes were generated from each tumor sample with oligo microarrays. A standard correlation-clustering algorithm identified 18 genes that co-clustered with estrogen receptor alpha. Eleven of these genes had previously been associated with estrogen regulation or breast tumorigenesis including trefoil factor 1 and estrogen regulated LIV-1. Additional study of these 18 genes may further delineate the role of estrogen receptor in breast cancer, generate new predictive biomarkers for response to endocrine therapies and identify novel therapeutic targets. The Pharmacogenomics Journal ( 
Genes that co-cluster with estrogen receptor alpha in microarray analysis of breast biopsies 
BACKGROUND
The estrogen receptor is a ligand-activated transcription factor containing hormone binding, DNA binding and transcription activation domains. 1 It is expressed in normal breast and 50-80% of breast cancers, depending on the assay used. [2] [3] [4] Estrogen receptor (ER) is a favorable prognostic factor and ER positive malignancies have a lower risk of relapse and a better overall survival. 5 However, ESR1 analysis is most useful in predicting response to endocrine therapies, although approximately half of all ER-positive cancers do not respond to antiestrogens or estrogen deprivation therapies. 6 The molecular basis for ESR1-positive, endocrine therapy-resistant disease is not well understood. Somatic mutations in ESR1 are rare, even in breast cancers that have acquired resistances to endocrine therapies. This finding has focused attention on other mechanisms, including the overexpression of tyrosone-kinase linked growth factor receptors, transcriptional coactivators such as AIB1 (amplified in breast cancer 1) or cell cycle regulators including Cyclin D1. Additional possibilities include mutations in other genes involved in the regulation of estrogen-dependent growth.
Expression of the estrogen-regulated genes, progesterone receptor (PGR) and trefoil factor 1 (TFF1 or PS2) indicate the presence of a functional and activated ER. 7 Both of these proteins are predictive biomarkers for breast cancer endocrine therapy, although less valuable than ER in distinguishing estrogen-dependent from estrogen-independent breast cancer. The use of PGR improves upon the predictive value of ER alone, yet ෂ 40% of tumors that express both ER and PGR fail to respond to endocrine treatments in the metastatic setting. 8 Similarly, TFF1 is associated with a good prognosis and predicts a positive response to hormonal therapy, but it has not proved to be sufficient as a predictive biomarker for routine evaluation of breast cancer. 9 Thus, PGR and TFF1 may be modestly useful in guiding the use of endocrine therapy. Additional markers are needed to more accurately predict endocrine therapy outcomes, particularly in the adjuvant setting. The expression of thousands of genes, including ESR1, PGR and TFF1 can now be determined simultaneously using microarray analysis. Single assays utilizing expression profiling could complement the predictive value of conventional IHC protocols through the examination of other genes downstream of ESR1 as well as other biomarkers that modulate the responsiveness to endocrine therapy. As a first step in the application of this technology to the problem of predicting endocrine therapy outcomes we have identified 18 genes with expression patterns similar to ERS1 in 51 breast tumor biopsies. . Breast cancer cell line MCF7 (ATCC) was grown in MEM ϩ 2 mM L-glutamine, 0.1 mM NEAA, 1 mM sodium pyruvate, 0.1 mM bovine insulin, 10% BSA to a confluency of 80%. All cell cultures were washed twice with ice cold PBS and then scraped from the dish, pelleted in cold PBS and snap frozen in liquid nitrogen.
MATERIALS AND METHODS

Cell
Sample Preparation
Twenty-one RNA samples were extracted from 14-gauge needle core biopsies collected before initiation of neoadjuvant endocrine therapy from patients enrolled in a randomized Phase III trial of letrozole (Femara, Novartis Pharma, Basel, Switzerland) vs tamoxifen for postmenopausal women with primary invasive breast cancer ineligible for breast conserving surgery. RNA was extracted from an additional 30 primary breast adenocarcinomas collected in Sweden, one additional ESR1 ϩ breast tumor surgical biopsy, two HUVEC samples, two samples from glioblastoma cell line U373-MG and one MCF7 sample using Trizol (Life Technologies, Gaithersburg, MD, USA). The clinical samples were collected after informed consent had been obtained according to protocols approved by local ethics committees. RNA was purchased for two samples, an infiltrating Stage III duct carcinoma (Ambion, Austin, TX, USA) and a pool of two normal breast tissues (Clontech, Palo Alto, CA, USA). The total number of samples prepared was 59 including 53 breast cancer biopsies and one pooled normal breast sample. Total RNA was purified using Qiagen RNeasy columns (Qiagen, Valencia, CA, USA), processed and hybridized to
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Immunohistochemistry
ER immunohistochemistry (IHC) was performed using standard protocols at the different hospitals where patient biopsies were collected.
Hierarchical Clustering
A 1156-gene subset of the HuGeneFL 6800 array was used as input for clustering due to computational limitations. This subset was comprised of those genes called present by GeneChip  Software (Affymetrix) in at least one of the 59 samples and that had a 20-fold difference in expression (average difference), between the normal pooled breast tissue sample and at least one of the 59 samples. This subset of genes ideally represented those genes that had some level of variation between normal samples and tumors. It excluded those genes that were either not expressed in any sample or did not vary significantly in at least one sample. Gene expression values were used to cluster genes and samples using GeneSpring  3.2.8 (Silicon Genetics, Redwood City, CA, USA), with the average difference measurement for each gene normalized across samples to a median of one. Gene expression similarity was measured by standard correlation with a minimum distance of 0.001 and a separation ratio of 0.5.
A list of genes co-clustering with ESR1 was compiled from the branch intersecting the primary node of the dendogram that contained the ESR1 gene. The branch was utilized to define the boundaries of the ESR1 co-cluster. Within this branch there were 12 sub-branches ( Figure 1 ). ESR1 resided in one of the sub-branches with three other genes; X-box binding protein 1, estrogen regulated LIV-1 and hepatocyte nuclear factor 3-alpha. Based on the standard correlation algorithm, the expression profile of these three genes has the highest correlation with ESR1. The list of genes co-clustering with ESR1 was expanded to the larger branch because many of the 18 genes in the primary branch have previously been reported to be regulated by the estrogen receptor.
RESULTS
Immunohistochemical and Microarray Data Correlation
Immunohistochemical analyses and microarray data were compared for ER and TFF1. Forty-eight of the breast tumor biopsies had associated ER IHC data. There was a strong correlation between the ER IHC calls and microarray expression data (r ϭ 0.662, P ϭ 0.000000306) using a Pearson Product Moment Correlation (Table 1 ). The median of the average differences, measurements of expression level, was 14.2 and 1456.6 for the ER negative and ER positive samples, respectively. Previously, a portion of the biopsies was used to examine the correlation between IHC and microarray expression data for TFF1 and reported by Coop et al. 11 The presence or absence of TFF1 determined by array and IHC was concordant in 75% (21/28, one assay failure) of biopsies. A significant correlation (Pearson r-value 0.463, P ϭ 0.013) between TFF1 mRNA and protein expression levels existed. 
Experimental Sample Tree
The samples with no or very low ESR1 expression primarily clustered near one end of the dendogram and the samples with high ESR1 expression clustered at the other end despite no clear branch delineating the two sample classes ( Figure  1 ). Ninety per cent (46/51) of samples clustered into their respective ER classes, based on IHC data. The average difference values for ESR1 ranged from Ϫ24.08 to 3501.6, with normal breast exhibiting a value of 124. The normal breast sample clustered at the border of the samples that generally had low expression for the 18 genes reported here and those samples with high expression (Figure 1 ). The mean of the ESR1 average difference for all samples that clustered above normal breast in Figure 1 was 66.37 with a standard deviation of 163.54. The mean of the ESR1 average difference for all samples that clustered below the normal breast sample was 1440 with a standard deviation of 936.
Endothelial and glioblastoma cell culture samples clustered with their respective cell types in branches distinct from the tumor biopsies. The endothelial and glioblastoma branches were located at the top end of the dendogram with low ESR1 expression (Figure 1 ). Their expression profiles for the ER cluster genes are quite distinct from that of the breast samples and MCF7 cell line. All of the genes in the ER cluster are absent or expressed at very low levels in the endothelial and glioblastoma cell lines. The ER positive samples have www.nature.com/tpj very high expression for most of the genes in Figure 1 and even the ER-negative samples have several of the genes expressed. Cell lines were included in the clustering analysis to improve the clustering of genes by providing cell types that may be present in breast tumors, such as endothelial and epithelial, as well as cell types that would be negative for the estrogen receptor transcriptome, such as glioblastoma.
Genes Co-clustering with ESR1
Eighteen genes co-clustered with ESR1 (Table 2) . These genes had a distinct pattern of high expression in the ESR1-positive samples and low expression in the ESR1-negative samples (Figure 1) . Seven of the genes that co-clustered with ESR1 had not previously been associated with estrogen stimulation or breast cancer: sodium channel, nonvoltagegated 1 alpha (SCNN1A), serine or cysteine proteinase inhibitor, clade A member 3 (SERPINA3), N-acylsphingosine amidohydrolase (ASAH), lipocalin 1 (LCN1), transforming growth factor-beta type III receptor (TGFBR3), glutamate receptor precursor 2 (GRIA2) and cytochrome P450, subfamily IIB (phenobarbital-inducible) CYP2B (Table 1) .
Six of the genes co-clustering with ESR1 have previously been considered to be estrogen-regulated proteins, predictive or prognostic biomarkers for breast cancer carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), LIV-1 protein (LIV-1), prolactin-induced pro- tein (PIP), matrix Gla protein (MGP), trefoil factor 3 (TFF3) and trefoil factor 1 (TFF1), also known as PS2 (Table 1) . CEACAM5 is an immunoreactive glycoprotein that is reportedly expressed in 10-95% of breast cancers. CEA-CAM5 protein level was found to be highest in ESR1ϩ/PGRϩ tumors in a study of 298 mammary tissue samples. 12 In addition to correlating with ESR1 expression, CEACAM5 was found to correlate with mammaglobin 1 (MGB1) expression in a report by Zach et al. 13 This same report also found that MGB1 levels correlated with estrogen receptor levels, supporting the gene clustering results (Figure 1) .
LIV-1 is a well-documented estrogen-regulated gene. It is induced by epidermal growth factor (EGF), transforming growth factor alpha (TGF␣) and insulin growth factor 1 (IGF1) through an ESR1-dependent mechanism.
14 PIP, alternatively known as gross cystic disease fluid protein 15, is induced by prolactin and androgen. PIP expression levels are correlated with ESR1 and PGR positive status. 15, 16 MGP belongs to the osteocalcin/matrix gla-protein family that associates with the organic matrix of bone and cartilage and is thought to act as an inhibitor of bone formation. Estrogen is a strong inducer of MGP gene expression. This induction can be blocked by retinoic acid. 18 Estrogen also strongly induces trefoil factors one and three. Trefoil factors are stable secretory proteins expressed in gastrointestinal mucosa. They may function to protect the mucosal epithelium from insults and aid healing.
19 TFF3 may be a predictive biomarker for breast cancer endocrine therapies. It is expressed in estrogen-responsive but not in estrogen-nonresponsive breast cancer cell lines and may play a role in promoting cell migration by controlling the expression of APC and E-cadherin-catenin complexes. 20, 21 As discussed previously, TFF1 is a fairly well established predictive biomarker for estrogen therapy responsiveness TFF1. mRNA levels are reportedly increased by estradiol but not by progesterone, dexamethasone, or dihydrotestosterone. 22 Furthermore, estradiol induction of TFF1 is reportedly inhibited by tamoxifen. 22 Another gene that co-clusters with ESR1, hepatocyte nuclear factor 3, alpha (HNF3A) activates TFF1 23 (Table 1) . HNF3A was shown previously to co-cluster with ESR1 in expression profiles from 65 breast tumors by Perou et al. 24 Three additional genes listed in Table 1 also co-clustered with ESR1 in the report by Perou et al: LIV-1; hepsin (HPN) a transmembrane protease which plays an essential role in cell growth and maintenance of cell morphology; 25 X-box binding protein 1 (XBP1) which binds to the HLA-DR-alpha promoter and may act as a transcription factor in B-cells. 26 Alpha-2-glycoprotein 1, zinc (AZGP1) is unique among the genes co-clustering with ESR1 in that it has not previously been associated with estrogen responsiveness but it has been considered as a biochemical marker of differentiation in breast cancer. 27 AZGP1 is a secreted protein that stimulates lipid degradation in adipocytes and may contribute to the extensive fat loss in patients with advanced cancer. It has high similarity to the extracellular domain of the alpha chain of class I MHC antigens.
28
DISCUSSION
Global analysis of gene expression at the mRNA level is a powerful tool for studying complex biological problems such as breast cancer. Clustering using standard correlation algorithms for expression array data was valuable in this study for identifying genes relevant to ESR1. Eighteen genes were found, including 11 genes known to be ESR1-regulated or associated with breast cancer tumorigenesis. Interestingly, four of the genes present in the ESR1 branch described here, LIV1, HPN, XBP1 and HNF3A were identified as members of a luminal epithelial ESR1 gene cluster described by Perou et al. 24 XBP1 was also associated with ESR1 status in a third report of gene expression profiling of breast tumors by Bertucci et al. 29 The co-clustering of HPN, HNF3A and XBP1 with ESR1 may be due to estrogen regulation, co-regulation by other factors, or association with some undefined breast cancer variability. Their potential as biomarkers for estrogen reactivity should be investigated. This is the first report of an association between estrogen receptor and the following seven genes, SCNN1A, SER-PINA3, ASAH, LCN1, TGFBR3, GRIA2, and CYP2B. Co-clustering of these genes with ESR1 may be: (1) coincidental; (2) due to their regulation by estrogen; (3) due to the fact that they are expressed in cell types that are ESR1-positive. For example, TGFBR3 and LCN1 are involved in cellular differentiation and proliferation and their de-regulation in a particular cell lineage that is also ESR1-positive in origin could result in tumorigenesis and co-clustering of ESR1 with these genes. [30] [31] [32] In addition to identifying genes that are co-regulated, hierarchical clustering of microarray data was used to distinguish sample types in this report. Glioblastoma cell samples clustered in one-branch and endothelial samples clustered in a neighboring branch of the dendogram that was distinct from the breast samples. The breast cancer samples, breast cell line and normal breast sample clustered into numerous branches consisting primarily of samples with like ESR1 expression. The complex tumor biopsy clustering dendogram illustrates the remarkable tumor heterogeneity that exists at the transcriptional level. It is striking that 90% of the tumors cluster with biopsies of like ER status despite the clustering being performed with a list of more than 1000 genes, most of which are independent of ESR1. It is likely that sample heterogeneity, such as amount of adi-
The Pharmacogenomics Journal pose tissue, stroma or genetic mutations influenced the clustering of some samples more strongly than the genes coclustering with ESR1. Consequently, the samples did not cluster into two distinct branches based on ER status. In an attempt to minimize the classes of tumors, the subset of 18 genes plus ESR1 was utilized to re-cluster the 59 experiments (data not shown). The resulting dendogram did not branch into two distinct ESR1-positive and ESR1-negative clusters. This suggests that the set of 18 genes co-clustering with ESR1 includes genes that are associated with some additional breast cancer variation such as ploidity or mutation.
The use of methods such as cytosol-based ligand-binding assays or immunohistochemistry to evaluate ESR1, PGR and TFF1 status is valuable in predicting endocrine therapy responsiveness, but a significant number of patients exhibit primary or acquired resistance to endocrine therapy despite the presence of these proteins. The identification of genes that co-cluster with ESR1 is a first step in the identification of new genes that may add to the predictive value of ESR1. Ultimately the ability to document a more complete picture of the estrogen-regulated transcriptome may lead to the desired level of predictive accuracy. Less invasive diagnostic assays that could be performed on blood would also be desirable since tumor tissue is not always accessible for profiling. We report here several genes associated with ESR1 expression that encode secreted proteins, TFF1, TFF3, SER-PINA3, PIP, MGP, TGFRB3 and AZGP1 that could form the basis for serum-based predictive biomarkers.
In conclusion, expression profiling of breast cancers was used to identify 18 genes that co-cluster with ESR1 including several for which this is the first report of an association. The 18 genes may be valuable for better delineating the estrogen receptor pathway and function, identifying surrogate markers of estrogen responsiveness, developing diagnostic assays and identifying potential therapeutic targets.
